高、低剂量重组人IL-2联合顺铂治疗恶性胸腔积液的疗效观察  

Therapeutic efficiency in the treatment of malignant pleural effusion by using high-dose、low-dose recombinant human interleukin-2 combined with cisplatin

作　　者：王妍[1] 沈进[2] 

机构地区：[1]辽宁省肿瘤医院内一科,辽宁沈阳110042 [2]沈阳市第五人民医院泌尿外科,辽宁沈阳110023

出　　处：《中国现代医生》2012年第13期66-67,共2页China Modern Doctor

摘　　要：目的探讨高、低剂量重组人白介素-2(IL-2)联合顺铂(PDD)胸腔灌注治疗肺癌伴恶性胸腔积液的临床疗效。方法 78例肺癌合并恶性胸腔积液的患者随机分为两组,高剂量组39例,胸腔内注入IL-2 300万U和PDD40 mg/m2;低剂量组39例,胸腔内注入IL-2 200万U和PDD 40 mg/m2,观察2组的临床疗效及不良反应。结果高、低剂量组总有效率分别为82.1%、61.5%,差异有统计学意义(P<0.05),两组毒副反应相近。结论高剂量IL-2联合PDD治疗恶性胸腔积液能显著提高疗效,且毒副反应轻微。Objective To observe the therapeutic efficiency in the treatment of malignant pleural effusion by using high- dose,low-dose recombinant human interleukin-2（IL-2） combined with cisplatin（PDD）. Methods Seventy-eight lung cancer patients with malignant pleural effusion were randomLy divided into two groups. High-dose group was 39 cases given 300-million unit IL-2 plus 40 mg/m^2 PDD; while low-dose group was 39 eases given 200-million unit IL-2 plus 40 mg/m2 PDD. The response and toxicity in the two groups were observed. Results The response rate in high-dose group and lowdose group were 82.1% and 61.5%,respectively, and had significant difference between the two groups（P 〈 0.05）. Adverse reaction was similar in the two groups. Condusion The high-dose IL-2 plus PDD can significandy improve the efficacy of the treantment of malignant pleural effusion and adverse reaction is mild.

关 键 词：重组人白介素-2 顺铂 恶性胸腔积液 

分 类 号：R730.5[医药卫生—肿瘤]